Pharmaceuticals
CEVA ANNOUNCES STRATEGIC LEADERSHIP CHANGES IN ASIA-PACIFIC AND CHINA
LIBOURNE, France, Feb. 9, 2026 /PRNewswire/ -- Ceva Animal Health
2026-02-09 14:00
6620
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2026-02-08 18:05
7120
Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
* Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards * Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals * Validated system provides reliable, consistent carbon footprint data for clients I...
2026-02-06 21:00
9802
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment ofHalle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Z...
2026-02-06 21:00
8287
LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders
BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2026-02-06 20:00
9970
Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...
2026-02-06 20:00
6654
Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
BASKING RIDGE, N.J., Feb. 6, 2026 /PRNewswire/ -- Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequi...
2026-02-06 19:59
4410
Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approv...
2026-02-06 17:00
6988
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...
2026-02-06 13:10
6853
Precision for Medicine Broadens Global Footprint with Singapore Office Opening
Singapore Office Expands APAC Presence to Seven Locations, Delivering Enhanced Local Expertise and Global Scale BETHESDA, Md., Feb. 6, 2026 /PRNewswire/ -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development, has announced the opening of...
2026-02-06 08:50
2017
World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rong...
2026-02-06 07:30
7696
Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combi...
2026-02-06 01:04
7965
Sore Back After Pre-New Year Cleaning? Herbalgy's "Wellness Declutter" Method Shares 3 Tips to Sweep Away Pain for a Light, Energetic New Year
HONG KONG, Feb. 5, 2026 /PRNewswire/ -- As Lunar New Year approaches, many households dive into their annual deep cleaning, hoping to start the year in a fresh, orderly environment. However, intensive cleaning in a short period—repeated bending, squatting, kneeling, or lifting, can quickly lead t...
2026-02-05 22:38
6693
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. * Unlike ISM8969, Insilico's brain-penetrant NLR...
2026-02-05 21:00
7546
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters:Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive developm...
2026-02-05 19:44
6446
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...
2026-02-05 17:09
7309
Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.
SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurolog...
2026-02-05 11:48
8054
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive ...
2026-02-05 08:17
5741
Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness
SEOUL, South Korea, Feb. 4, 2026 /PRNewswire/ -- Yuyu Pharma announced today a strategic investment in James & Ella, theUnited Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneurJames Middleton, James & Ella has rapidly established itself as the leader of the UK ...
2026-02-04 22:00
5495
Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting ...
2026-02-04 21:00
4156
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 316 media titles]
2026-03-27 11:15
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 310 media titles]
2026-03-24 14:00Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 279 media titles]
2026-03-25 16:51
Noah Reports Q4 and Full Year 2025 Earnings: Structural Transformation Driving Significant Improvement in Profitability as AI Integration Drives Operational Efficiency
[Picked up by 274 media titles]
2026-03-25 21:58